News
ZIVO
2.535
-19.78%
-0.625
ZyVersa, Aziyo top healthcare gainers; Cidara, Protagenic among losers
Seeking Alpha · 7h ago
Maxim Group Keeps Their Buy Rating on Zivo Bioscience (ZIVO)
TipRanks · 6d ago
9 Consumer Staples Stocks Moving In Monday's Intraday Session
Benzinga · 02/13 17:31
Pre-market Movers: GTHX, VLON, ZIVO, ACGN, OCUL…
NASDAQ · 02/13 12:47
--Maxim Adjusts ZIVO Bioscience Price Target to $6 From $9
--Maxim Adjusts ZIVO Bioscience Price Target to $6 From $9
MT Newswires · 02/13 12:35
BRIEF-Zivo Bioscience Announces Results Of Study With Its Coccidiosis Drug In Broiler Chickens
Reuters · 02/10 21:50
9 Consumer Staples Stocks Moving In Tuesday's Intraday Session
Benzinga · 12/13/2022 17:33
BRIEF-Zivo Bioscience Has Received Notice Of Delisting From Nasdaq
Reuters · 11/29/2022 21:43
BRIEF-Zivo Bioscience Establishes Zivolife Agtech Business
Reuters · 10/24/2022 22:26
ZIVO Bioscience Announces Plans For A New Streamlined, Focused Corporate Structure And Establishes The ZIVOLife Agtech Business
Benzinga · 10/24/2022 20:19
ZIVO Bioscience CEO Issues Letter to Shareholders
BLOOMFIELD HILLS, Mich., September 23, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued th...
Business Wire · 09/23/2022 12:00
BRIEF-Zivo Bioscience Inc Announces Receipt Of A Letter From The U.S. Department Of Agriculture's Center For Veterinary Biologics
BRIEF-Zivo Bioscience Inc Announces Receipt Of A Letter From The U.S. Department Of Agriculture's Center For Veterinary Biologics
Reuters · 08/23/2022 11:43
Zivo Bioscience Said USDA Letter Affirmed Agency Has Claimed Jurisdiction for Reviewing the Company's Novel Immune-Modulating Biologic for Treating Coccidiosis in Broiler Chickens
In August 2022, Zivo Bioscience, Inc. (the "Company") announced receipt of a letter from the U.S. Department of Agriculture's (USDA) Center for Veterinary Biologics (CVB) affirming that the agency has claimed jurisdiction for reviewing the Company's novel immune-modulating biologic for treating coccidiosis in broiler chickens.
Benzinga · 08/23/2022 11:38
Why Amazon Shares Traded Lower; Here Are 74 Biggest Movers From Yesterday
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 72.8% to close at $2.16 on Monday as the stock continued to see momentum despite the company last week announcing it is not aware of any developments that would explain the recent surge.
Benzinga · 08/23/2022 10:11
BRIEF-Zivo Reports That USDA Claims Regulatory Jurisdiction For New Coccidiosis Treatment
BRIEF-Zivo Reports That USDA Claims Regulatory Jurisdiction For New Coccidiosis Treatment
Reuters · 08/10/2022 20:59
ZIVO Reports that USDA Claims Regulatory Jurisdiction for New Coccidiosis Treatment
BLOOMFIELD HILLS, Mich., August 10, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, an...
Business Wire · 08/10/2022 20:15
Zivo Bioscience Joins Russell Microcap Index
ZIVO Bioscience, Inc. (NASDAQ:ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal
Benzinga · 06/27/2022 12:10
Zivo Bioscience joins Russell Microcap® Index
ZIVO Bioscience (NASDAQ:ZIVO) has joined the Russell Microcap® Index, effective from June 27, 2022. “Our inclusion reflects continued interest in our stock along with long- and near-term growth expectations as
Seekingalpha · 06/27/2022 12:09
Zivo Bioscience Joins Russell Microcap® Index
BLOOMFIELD HILLS, Mich., June 27, 2022--ZIVO Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, toda...
Business Wire · 06/27/2022 12:00
ZIVO Bioscience regains compliance with Nasdaq continued listing rule
ZIVO Bioscience (NASDAQ:ZIVO) has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company received a noncompliance notice Nasdaq last week for failing to timely file its 2021 annual report on
Seekingalpha · 04/25/2022 20:47
More
Webull provides a variety of real-time ZIVO stock news. You can receive the latest news about Zivo Bioscience Inc through multiple platforms. This information may help you make smarter investment decisions.
About ZIVO
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its products include Poultry Gut Health, Bovine Mastitis, Canine Joint Health, Human Immune Modification, Algal biomass for human consumption and Biomass for supporting skin health / anti-aging. The Company is also engaged in licensing and selling natural bioactive ingredients derived from their algae cultures to animal, human and dietary supplement and medical food manufacturers. Its product candidates are at different stages of development for different applications.